Transcatheter aortic valve replacement (TAVR) is sweeping the country. The dramatic outcomes in patients with aortic stenosis and no surgical option started the stampede. Trials of patients who were surgical candidates, from high to moderate surgical risk, showed that TAVR outcomes were at least as good as open surgery. The final nail in the open surgery coffin was the trial in low-surgical-risk patients, PARTNER 3 . The one-year outcomes with TAVR were superior to open surgery, and the message has been put into practice as the large majority of aortic valve replacements for aortic stenosis are TAVR.